was established in the year 1992 as a 100% Export Oriented Unit. Commencing operations in February 1994, company achieved rapid growth to emerge as the one of the largest company in the Indian pharmaceutical industry in a short span of years. Company employs over 4000 people; over 700 of them are scientists, technologists and other professionals. Company has long-term exclusive agreements with reputed companies such as Apotex, Par, Alpharma, Stada and Mayne for distribution of Orchid’s products in the regulated markets of US and Europe. Orchid, at its R&D Centers and along with its US subsidiary for drug discovery, is actively involved in discovery of new drugs.

Orchid is globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well as in drug discovery. Company has been investing aggressively and continually for establishing modern research and manufacturing facilities aimed at global markets, thus emerging as a world-class pharmaceutical company covering the entire value chain from Discovery to Delivery.

In formulations, company manufactures anti-infective, Anti-inflammatory, Anti-oxidants, Anti-ulcerant, CNS, CVS, Nutraceuticals and Oral Anti-Diabetic. Company has two manufacturing sites for APIs (at Alathur near Chennai and at Aurangabad, near Mumbai) and three manufacturing sites for Dosage forms (at Irungattukottai and Alathur in Chennai), besides a world-class R&D centre (at Sholinganallur, Chennai). Orchid’s facilities are state-of-the-art and have several international regulatory approvals, including the US FDA and UK MHRA. Orchid’s API facilities are ISO certified for their quality, environmental management and operational health and safety systems. Orchid has a Joint Venture in China for manufacturing sterile APIs. Orchid has an established end-to-end connected infrastructure for drug discovery and development which are channeled through its subsidiaries, Orchid Research Laboratories in Chennai and Bexel Pharmaceuticals in the US. With the help of superior infrastructure and by adopting a judicious blend of structure-based drug design approach, Orchid has been able to simultaneously work on several therapeutic programs with several lead compounds in advanced stages of trials. Orchid has also entered into Contract Research initiatives with key multinational companies

In July 2010, Orchid Chemicals & Pharmaceuticals has received the tentative approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for its generic drug Gemifloxacin Mesylate tablets in 320 mg strength. Gemifloxacin mesylate is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. In august 2010, company has received approval from the US Food and Drug Administration (US FDA) for its ANDA (Abbreviated New Drug Application) for Levetiracetam Tablets, 1000 mg.

Orchid Chemicals and Pharmaceuticals is one of the reputed pharmaceutical firms in India and the largest manufacturer and exporter of Cephalosporin bulk actives in India. At CMP, Stock is trading at 7.4 P/E multiple of its FY2012 estimated earnings. We recommend investors to”BUY” “Orchid chemicals and pharmaceuticals limited” with medium to long-term investment prospective.